Tumor phenotype and characteristics of metastatic brain involvement in breast cancer patients: Potential clinical consequences

PALÁCOVÁ, Markéta, Marek SVOBODA, Pavel FABIAN, Barbora ONDROVÁ, Peter GRELL, Jana GOMBOŠOVÁ, Denis PRINC, Lenka RADOVÁ, Pavel ŠLAMPA and Rostislav VYZULA. Tumor phenotype and characteristics of metastatic brain involvement in breast cancer patients: Potential clinical consequences. In Journal of Clinical Oncology - supplementum. 1st ed. Alexandria, VA 22314, USA: American Society of Clinical Oncology, 2009, p. 15-15. ISSN 1527-7755.

Basic information

• Original name: Tumor phenotype and characteristics of metastatic brain involvement in breast cancer patients: Potential clinical consequences
• Name in Czech: Fenotyp nádoru a charakteristika metastatického postižení mozku u pacientek s karcinomem prsu: potenciální klinické konsekvence.
• Authors: PALÁCOVÁ, Markéta, Marek SVOBODA, Pavel FABIAN, Barbora ONDROVÁ, Peter GRELL, Jana GOMBOŠOVÁ, Denis PRINC, Lenka RADOVÁ, Pavel ŠLAMPA and Rostislav VYZULA.
• Edition: 1. vyd. Alexandria, VA 22314, USA, Journal of Clinical Oncology - supplementum, p. 15-15, 1 pp. 2009.
• Publisher: American Society of Clinical Oncology

Other information

• Original language: English
• Type of outcome: Proceedings paper
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United States of America
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 17.793
• Organization unit: Faculty of Medicine
• ISSN: 1527-7755
• UT WoS: 000276606601503
• Keywords (in Czech): karcinom prsu;metastazy;CNS
• Keywords in English: breast cancer;metastasis;CNS
• Tags: International impact, Reviewed

Abstract

Background: Central nervous system metastases (CNS) occur in about 20% of patients with breast cancer. Despite the fact that most of these patients die within a few months, substantial subgroup may survive a year or more. Methods: We performed this study on cohort of 187 breast cancer patients who developed CNS metastases to identify relations between the tumor phenotype and the incidence and characteristics of CNS dissemination, response to the local therapy and overall survival since the development of metastases in brain (OScns). Results: The incidence of monitored phenotypes and other data are included in the table. An unambiguous dependence between the tumor's phenotype and the following attributes has been proven: a) interval between the disease diagnosis and the 1st metastatic event (DFS); b) interval between the 1st metastatic event and the metastases in the CNS (TTPcns); c) characteristics of CNS dissemination. The CNS dissemination was the most extensive in patients with HER-2+ tumors in comparison with HER-2 negat. carcinomas. Surprisingly, patients with triple-negative tumors had the minimal metastatic involvement of CNS defined by size and number of lesions. Phenotype did not correlate with local response to therapy and OScns. The OScns has been significantly prolonged by neurosurgery (median 13,8 vs 2,4 months, p<0.0001) and when the effective local treatment was followed by system treatment (6,1 vs 1,9 months, p<0.0001). Conclusions: Our study has confirmed the dependence between primary tumor phenotype and the time of incidence of metastatic brain affection and character of their spread. Our results encourage the inclusion of CNS imaging examination (CT or MRI) into the regular restaging of patients with HER2 positive and triple-negative primary breast cancer, who are at high

Abstract (in Czech)

only in English: Background: Central nervous system metastases (CNS) occur in about 20% of patients with breast cancer. Despite the fact that most of these patients die within a few months, substantial subgroup may survive a year or more. Methods: We performed this study on cohort of 187 breast cancer patients who developed CNS metastases to identify relations between the tumor phenotype and the incidence and characteristics of CNS dissemination, response to the local therapy and overall survival since the development of metastases in brain (OScns). Results: The incidence of monitored phenotypes and other data are included in the table. An unambiguous dependence between the tumor's phenotype and the following attributes has been proven: a) interval between the disease diagnosis and the 1st metastatic event (DFS); b) interval between the 1st metastatic event and the metastases in the CNS (TTPcns); c) characteristics of CNS dissemination. The CNS dissemination was the most extensive in patients with HER-2+ tumors in comparison with HER-2 negat. carcinomas. Surprisingly, patients with triple-negative tumors had the minimal metastatic involvement of CNS defined by size and number of lesions. Phenotype did not correlate with local response to therapy and OScns. The OScns has been significantly prolonged by neurosurgery (median 13,8 vs 2,4 months, p<0.0001) and when the effective local treatment was followed by system treatment (6,1 vs 1,9 months, p<0.0001). Conclusions: Our study has confirmed the dependence between primary tumor phenotype and the time of incidence of metastatic brain affection and character of their spread. Our results encourage the inclusion of CNS imaging examination (CT or MRI) into the regular restaging of patients with HER2 positive and triple-negative primary breast cancer, who are at high risk

Links

• NS10357, research and development project: Name: Epidemiologické, genetické a klinicko-patologické aspekty ?triple-negativního? (ER-?, PR, c-ErbB2 negativního) karcinomu prsu v populaci českých žen.